2024 年度业绩预告 证券代码:300463 证券简称:迈克生物 公告编号:2025-008 迈克生物股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或者重大遗漏。 （二）业绩预告情况：□亏损 □扭亏为盈 □同向上升 √同向下降 | 项 目 | 本报告期 | 上年同期 | | --- | --- | --- | | 归属于上市公司股 东的净利润 | 盈利：12,000.00 万元~18,000.00 万元 | 万元 盈利：31,261.86 | | | 比上年同期下降：61.61%~42.42% | | | 扣除非经常性损益 后的净利润 | 盈利：11,800.00 万元~17,700.00 万元 | 盈利：31,565.80 万元 | | | 比上年同期下降：62.62%~43.93% | | 二、与会计师事务所沟通情况 公司 2024 年度业绩预告相关的财务数据是公司财务部门初步核算的结果，未经会计师 事务所审计。公司已就业绩预告有关事项与年报审计会计师事务所进行了预沟通，公司与会 计师事务所在业绩预告方面不存在分歧。 三、业绩变动原因说明 第 1 页 ...

大家下午好那个非常欢迎参加由国联证券主办国胜证券国信证券华泰证券中庆箭头共同写办的麦克生物的三级报交流会同时呢还有我们同事林爱玲那么今天参会的领导是董事会秘书石石伟石总财务总监尹山寅总以及销售总监赤人波崔总 那么下面我们就正常进行这个会议的会议的内容那么想先请那个石总或者公司的领导帮我们再介绍一下三级报的一些具体的细节尤其是可能这两年大家比较关注的像集财啊这些再帮我们做一些政策的这个展望吧谢谢好的好那个谢谢各位投资者 也欢迎大家参加麦克生物2024年的第三季度报告的电话沟通会那么在2024年我们说过去的这三个季度其实我们也是面临到一个市场环境的这样子的一个变化和一个挑战那么公司在这个过程当中的话我们也是继续保持着我们的一个战略的定力和我们的 23年以来我们推进的一些市场的策略那么主要体现在我们在推进智慧化实验室整体解决方案的一个持续落地那么同时我们也在加大我们核心产品的一个持续投入那么另外的话还有就是我们也在加快公司在渠道整合方面的一些工作那么我们是持续去进行一些优化集中我们的一些资源优势 那从整个的这个三级报的这个报表的情况来看的话可以说单三季度的话业绩的增长是有所下滑的那么具体的情况我是从先从两个层面去跟 ...

1、经营业绩介绍 2024 年前三季度，市场环境充满挑战，公司在保持战略定力和既定市场策略的同时， 持续推进智慧化实验室整体解决方案的落地和核心产品的研发投入，集中优势资源， 加快渠道整合与优化。 收入端，前三季度实现营业收入 19.47 亿，同比下降 7.92%，单三季度同比下降 8.94%。其中自主产品收入 14.32 亿元，占比 73.55%，同比增长 6.55%，自主产 品第三季度同比增长为 3.39%。非自主产品业务实现收入 5.15 亿，占比 26.45%， 同比下降 32.42%，单三季度同比下降 32%。 利润端，前三季度实现归母净利润 2.81 亿，同比增长 4.72%。单三季度同比下降 15.13%。主要系收入下降、研发投入与销售费用增长导致。另一方面虽然营收下滑、 自主产品业务增长放缓，但业务整合带来了运营效率的改善，自主产品的增长和资产 减值损失的改善对利润有积极影响。综合毛利率约 58%，较 23 年略有提升，主要受 益于产品结构调整导致。 2、业务进展介绍 流水线及主要仪器情况：2024 年 1~9 月新增流水线安装 233 条，累计已安装 723 条；其中四大流水线 2024 年 ...

证券代码:300463 证券简称:迈克生物 迈克生物股份有限公司 | --- | --- | --- | |-----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Financial Performance - Revenue for the third quarter was RMB 668.7 million, a decrease of 8.94% year-over-year[2] - Net profit attributable to shareholders was RMB 79.65 million, down 15.13% compared to the same period last year[2] - Operating income for the period was 1,947,615,476.64, down from 2,115,080,245.60 in the previous period, showing a decline in revenue[19] - Net profit attributable to the parent company's owners rose to 4,027,733,640.18 from 3,840,419,554.17, demonstrating improved profitability[18] - Net profit attributable to parent company shareholders was 281.37 million yuan, compared to 268.68 million yuan in the same period last year[20] - Basic earnings per share were 0.4635 yuan, compared to 0.4387 yuan in the same period last year[21] - Total comprehensive income was 274.05 million yuan, compared to 251.12 million yuan in the same period last year[21] - The company reported a revenue increase of 15% year-over-year, reaching $1.2 billion[24] - Net profit grew by 20% compared to the previous year, totaling $250 million[24] - The company forecasts a 12% revenue growth for the next fiscal year, targeting $1.34 billion[24] Cash Flow and Financial Position - Operating cash flow decreased by 20.11% to RMB 493 million, primarily due to a decline in cash received from sales of goods and services[11] - Investment cash flow outflows increased by 77.90% to RMB 540.24 million, mainly due to increased investment in the IVD Industrial Park[11] - Financing cash flow turned positive to RMB 43.97 million, a significant improvement from a negative RMB 133.09 million in the same period last year[11] - Cash flow from operating activities was 492.99 million yuan, compared to 617.12 million yuan in the same period last year[23] - Cash flow from investing activities was -540.24 million yuan, compared to -303.68 million yuan in the same period last year[23] - Cash flow from financing activities was 43.97 million yuan, compared to -133.09 million yuan in the same period last year[23] - Cash and cash equivalents at the end of the period were 806.06 million yuan, compared to 746.99 million yuan in the same period last year[23] - The company's monetary funds at the end of the period are 829,961,103.27 yuan, a slight decrease from 835,957,326.80 yuan at the beginning of the period[16] - Total assets increased to 8,205,887,219.80 from 8,119,249,307.93, indicating a growth in the company's overall financial position[17] - Total liabilities decreased to 1,587,537,950.88 from 1,507,787,287.39, reflecting a reduction in the company's debt obligations[18] - Short-term borrowings rose to 340,741,907.47 from 144,647,498.10, indicating increased short-term financing needs[17] - Deferred tax liabilities decreased to 167,866,698.96 from 179,073,594.69, suggesting changes in tax planning strategies[18] - Minority interests decreased to 83,161,408.83 from 226,636,750.20, reflecting changes in ownership structure[18] Investments and Capital Expenditures - The company's investment in the Tianfu International Bio-City IVD Industrial Park increased by 41.29%, reaching RMB 1.01 billion[7] - Fixed assets increased to 2,295,945,340.09 from 2,186,644,511.57, reflecting ongoing capital investments[17] - The company plans to invest $100 million in new product development over the next fiscal year[24] - A new merger with a biotech firm is anticipated to close by Q2 2025, adding $150 million to annual revenue[24] - R&D expenditure increased by 18%, reaching $200 million for the fiscal year[24] Shareholder and Ownership Structure - The total number of ordinary shareholders at the end of the reporting period is 37,858[12] - Tang Yong holds 11.11% of the shares, totaling 68,062,301 shares, with 51,046,726 shares under restricted conditions[12] - Wang Dengming holds 7.43% of the shares, totaling 45,534,495 shares, with 34,150,871 shares under restricted conditions[12] - Guo Lei holds 5.84% of the shares, totaling 35,774,906 shares, all of which are unrestricted[12] - Liu Qilin holds 5.41% of the shares, totaling 33,127,360 shares, with 24,845,520 shares under restricted conditions[12] - Chen Mei holds 4.30% of the shares, totaling 26,320,900 shares, all of which are unrestricted[12] - Wang Chuanying holds 3.69% of the shares, totaling 22,627,862 shares, all of which are unrestricted[12] - Hong Kong Securities Clearing Company holds 2.23% of the shares, totaling 13,646,844 shares, all of which are unrestricted[12] - The total restricted shares at the end of the period amount to 120,964,773 shares, an increase of 3,844,966 shares from the beginning of the period[15] Operational Efficiency and Cost Management - Operating costs decreased to 1,641,999,626.83 from 1,749,690,942.20, indicating improved cost management[19] - R&D expenses increased to 223,099,816.06 from 217,166,769.19, highlighting the company's continued investment in innovation[19] - The company introduced a new AI-driven diagnostic tool, which is projected to increase efficiency by 25%[24] Market Expansion and Strategic Partnerships - Market expansion into Southeast Asia is expected to contribute an additional $300 million in revenue by 2025[24] - A new strategic partnership with a leading healthcare provider is expected to boost market share by 5%[24] Impairment and Credit Losses - The company's credit impairment loss decreased by 147.53% to RMB -19.07 million, mainly due to a reduction in accounts receivable[10] - Asset impairment loss decreased by 87.07% to RMB -54.33 million, primarily due to a reduction in inventory impairment losses[10] User Base and Revenue Streams - User base expanded by 10%, now standing at 5 million active users[24] - Sales revenue from goods and services was 2.25 billion yuan, compared to 2.65 billion yuan in the same period last year[22] - Cash received from tax refunds was 36.05 million yuan, compared to 62.21 million yuan in the same period last year[22] - Cash paid for goods and services was 975.38 million yuan, compared to 1.22 billion yuan in the same period last year[22]

证券研究报告 | 2024年08月11日 迈克生物（300463.SZ） 优于大市 单二季度归母净利同比增长 40%，自产试剂快速放量 单二季度归母净利润同比增长 40%，加快代理产品剥离及重塑自主产品经销 体系。2024 年上半年公司实现营收 12.79 亿（-7.37%），归母净利润 2.02 亿（+15.38%），扣非归母净利润 1.99 亿（+11.49%）；其中单二季度营收 6.63 亿（-5.93%），归母净利润 0.81 亿（+40.23%）。近两年公司加快代 理产品剥离以及重塑自主产品经销体系的调整速度，自主产品保持稳健增长 且收入占比提升较快，且自主产品成本优势远高于代理产品，自主产品销售 增长和结构提升将驱动业绩增长，自主产品净利润贡献由 2019 年 75.27%提 升至 87.24%。 自主产品试剂销量同比增长 23%，持续推进大型仪器及流水线的终端装机。 2024 年上半年自主产品收入 9.32 亿（+7.61%），毛利率为 72.42%（+1.54pp）； 其中自主产品试剂收入 8.59 亿（+5.9%），试剂销量同比增长 23.4%，收入 增速慢于销量的主要原因是受到了集采政策落 ...

2023042 公司点评报告 ·医药行业 24Q2 利润高速增长,流水线驱动未来成长 2024 年中报业绩点评 核心观点 ● 事件:公司发布 2024年半年度报告,2024年 1~6 月实现营业收入 12.79 亿 元（-7.37%），归母净利润 2.02 亿元（+15.38%），扣非净利润 1.99 亿元 (+11.49%),经营性现金流 2.13 亿元(-48.09%)。2024Q2 实现营业收入 6.63 亿元(-5.93%),归母净利润 0.81 亿元(+40.32%),扣非净利润 0.81 亿元(+39.45%),经营性现金流 2.08 亿元(-14.37%)。 ● 自主产品增长驱动业绩改善,代理产品业务进一步剥离:1自主产品:2024 年 1-6 月公司自主产品业务实现销售收入 9.32 亿元(+7.61%),收入占比已 由 2019年的 37.73%提升至 72.91% (+35.18pct)，净利润贡献已由 2019年 的 75.27%提升至 87.24%(+11.97pct); 2024H1 自主试剂产品销量同比增 长 23.4%,实现收入 8.59 亿元(+5.9%),毛利率 72.42% ...

股 票 研 究 证 券 研 究 报 告 ——2024 年半年报点评 自主产品平稳增长，流水线进展顺利 迈克生物(300463) [Table_Industry] 医药/必需消费 | --- | --- | --- | |----------|-----------------------------------|-----------------------| | | | | | | [table_Authors] 丁丹 ( 分析师 ) | 赵峻峰 ( 分析师 ) | | | 0755-23976735 | 0755-23976629 | | | dingdan@gtjas.com | zhaojunfeng@gtjas.com | | 登记编号 | S0880514030001 | S0880519080017 | 本报告导读： 公司持续加大研发投入以及流水线市场推广，同时也在不断提升管理效率、降本增 效，随着自主产品占比的提升，业绩平稳增长，维持增持评级。 投资要点： 公 司 更 新 报 告 [Table_Summary] 维持增持评级。维持 2024~2026 年 EPS 预测 0.71/0.86/1. ...

证券研究报告 非金融公司 | 公司点评 | 迈克生物 (300463) 流水线装机亮眼，逐步带动试剂放量 请务必阅读报告末页的重要声明 2024年08月03日 券研究报告 |报告要点 公司发布 2024 年半年报，2024 年上半年实现收入 12.79 亿元，同比下滑 7.37%: 实现归母净 利润 2.02 亿元，同比增长 15.38%；实现扣非后归母净利润 1.99 亿元，同比增长 11.49%。 | 分析师及联系人 郑藏 SAC: S0590521070002 请务必阅读报告末页的重要声明 1 / 5 非金融公司 | 公司点评 2024年08月03日 迈克生物(300463) 流水线装机亮眼,逐步带动试剂放量 | --- | --- | |-------------------------|-------------------------------| | | | | 行 业: 授资评级: | 医药生物/医疗器械 买入 (维持) | | 当前价格: | 11. 73 元 | | 基本数据 | | | 总股本/流通股本(百万股) | 612. 47/491. 50 | | 流過 A 股市值(百万元) | ...

证券代码:300463 证券简称:迈克生物 迈克生物股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |------------|-----------------------|-------------|------------------| | | | | 编号：2024-IR003 | | | □特定对象调研 | ■分析师会议 | | | 投资者关系 | □媒体采访 □业绩说明会 | | | | 活动类别 | □新闻发布会 □路演活动 | | | | | □现场参观 | | | □其他（请文字说明其他活动内容） 华泰证券、国信证券、国联证券、国盛证券、东方证券、中信建投证券、中信 证券、中金公司、华安证券、华鑫证券、国投证券、野村证券、长江证券、银 河证券、太平洋证券、方正证券、申万宏源证券、国泰君安证券、建信养老金 参与单位名称 管理有限责任公司、东方证券资产管理有限公司、高毅资产、源峰基金、相聚 资本、长信基金、国盛资管、灏浚投资、众信资产、凯丰投资、北京弘道投 资、华强金控、APS 资产管理、康曼德资本共 32 家机构的 42 名参会人员。 时间 2024 年 ...